Adekin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adekin

Quick Facts

Property Description
Active ingredient Cyproheptadine hydrochloride
Form Tablet, Oral solution, Syrup
Pharmacological class First-Generation Antihistamine
Common use Alleviating allergy symptoms, appetite stimulation
Origin Synthetic chemical compound

Adekin is a specific brand name for a prescription medicine containing the active ingredient Cyproheptadine hydrochloride, which is pharmacologically classified as a first-generation antihistamine. This designation confirms that the medicine primarily works by targeting histamine receptors. As a synthetic compound, it belongs to the piperidine chemical group and is manufactured as a single-ingredient product.

What Pharmacological Class Does Adekin Belong To?

Adekin is designated as an H1-antihistamine that works by competing with histamine for binding at H1 receptor sites, thereby counteracting the effects of this key substance released during allergic reactions. The compound’s structure allows it to readily enter the central nervous system, classifying it as a sedating agent, which differentiates it from newer compounds. Its general purpose is clinically recognized for modulating the body's inflammatory responses, and it is frequently referenced in research for its significant effects on neurochemical pathways.

Composition and Available Pharmaceutical Forms

The core composition of Adekin is the active component, Cyproheptadine hydrochloride, combined with inert excipients necessary for the preparation. The medicine is manufactured for oral administration and is typically supplied as a tablet or a syrup (oral solution). Adekin's availability in a syrup form is a distinct feature, as it offers a more palatable option compared to tablets, facilitating its use in pediatric patients or individuals who may experience difficulty swallowing solid preparations.

The Unique Dual Action of Cyproheptadine

The medicine's broad therapeutic function is derived from its dual mechanism, acting not only as a potent histamine H1 receptor antagonist but also as an effective antagonist of serotonin receptors. This dual action is a recognized characteristic of the compound. This secondary action in modulating the serotonin system is the biological basis for its established utility in specific areas, including appetite stimulation and the management of certain neurovascular discomforts, offering a distinctive spectrum of benefits compared to antihistamines focused solely on H1 receptors.

Regulatory References

  1. Scientific literature consistently confirms this unique dual action (NIH/LiverTox)

What side effects are possible with Adekin?

Adekin (Cyproheptadine hydrochloride) is an orally administered medication, and its official safety profile, as documented in regulatory sources, is primarily characterized by effects related to Central Nervous System (CNS) activity and anticholinergic properties.

Documented Adverse Reactions

The most frequently classified adverse reactions are drowsiness and somnolence, which are categorized as Common (1% to 10%) in official prescribing information. Regulatory documents specify that these sedative effects are often transient and may lessen after the first few days of continuous administration.

Adverse effects span multiple System-Organ Classes, though most are not assigned a specific frequency category. These include:

System-Organ Class Examples of Documented Effects
Nervous System Dizziness, disturbed coordination, tremor, confusion, excitation
Gastrointestinal Dry mouth, nausea, constipation, epigastric distress
Metabolism Increased appetite and associated weight gain

Serious Adverse Reactions and Safety Constraints

Officially documented serious adverse reactions include rare but clinically significant events such as hepatic failure, convulsions, severe hypotension, and anaphylactic shock. The label also notes the risk of severe psychiatric events, including hallucinations.

Safety is structured by several absolute contraindications. Adekin must not be used in neonates or premature infants due to the risk of serious respiratory complications, nor in debilitated geriatric patients. Use is also strictly restricted in individuals with conditions like narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, or those concurrently using Monoamine Oxidase Inhibitors (MAOIs), as this combination can intensify anticholinergic effects.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Adekin carries a substantial risk of severe hepatotoxicity, which can rapidly progress to acute liver failure, the necessity for a liver transplant, and death. This severe outcome is the central focus of regulatory warnings regarding overexposure to the drug's active substance.

Documented Overdose Presentation and Risk Factors

Initial signs of overdose often include non-specific symptoms such as nausea, vomiting, malaise, and abdominal pain. Critically, these symptoms may be subtle or delayed, sometimes not appearing for 12 or more hours post-ingestion, and can mimic common flu or cold symptoms. The absence of symptoms immediately following a suspected overdose does not mean toxicity will not develop.

Risk of severe toxicity is increased for patients who simultaneously use multiple products containing the active substance (unintentional overdose) or who have pre-existing liver disease or a history of heavy, chronic alcohol consumption.

Emergency Response and Time-Critical Action

Immediate emergency medical attention is required for any known or suspected overdose. This action is critical because the effectiveness of the antidote administered by medical professionals is critically time-dependent. Treatment initiated within the first 8 hours of an acute ingestion offers the most favorable prognosis for preventing permanent liver damage. Delaying medical help significantly reduces the chance of a successful outcome and increases the risk of life-threatening complications.

Therapeutic Uses of Adekin

Adekin is commonly used in therapeutic contexts relevant for easing symptoms related to physical discomfort and is considered relevant in other supportive therapeutic domains. This medicine is applied across domains where additional symptomatic support is needed, primarily addressing allergic-inflammatory symptoms, poor nutritional state, and recurrent neurovascular discomfort.

It helps address symptom clusters that may become intense or disruptive, such as persistent sneezing, intense pruritus (itching), and the lack of appetite (anorexia) that may create noticeable physiological strain. The medication is commonly used to help with allergic rhinitis (seasonal and perennial), urticaria (hives), and other allergic skin conditions. It is also relevant for easing the symptoms of migraine (used in contexts involving recurrent or episodic manifestations) and is applied to help with appetite stimulation and weight gain support, particularly in pediatric patients who experience nutritional strain.

“The medication may assist with managing symptoms that create noticeable physiological strain across various symptomatic phases.”

Quick Fact: Relief for Key Symptoms
Symptom Axes Allergic irritation, Nutritional strain, Episodic head discomfort
Common Scenarios Seasonal allergy flare-ups, Chronic poor appetite, Recurrent vascular headaches
Primary Benefit Contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Adekin?

Eligibility for Adekin (Cyproheptadine) is strictly defined by regulatory guidelines and official prescribing information, primarily based on age, physiological status, and pre-existing medical conditions.


Official Eligibility Constraints

Category Official Regulatory Status
Approved Age Children 2 years of age and older, adolescents, and adults.
Use Not Established Safety and effectiveness not established for children under 2 years of age.
Geriatric Use Use with caution in the elderly; contraindicated in debilitated geriatric patients.
Pregnancy/Lactation Category B in pregnancy (use only if clearly needed); Contraindicated in nursing mothers.

Absolute Contraindications

Adekin must not be used in patients with the following conditions, as stated in regulatory labels:

  • Infants (newborn or premature).
  • Ocular Conditions: Angle-closure glaucoma.
  • Gastrointestinal Obstruction: Stenosing peptic ulcer or pyloroduodenal obstruction.
  • Urogenital Obstruction: Bladder neck obstruction or symptomatic prostatic hypertrophy.

Use requires caution in patients with a history of bronchial asthma, hyperthyroidism, or existing hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Adekin (Cyproheptadine) outlines specific interaction patterns, primarily categorized by the risk of reinforced depressant effects.


Formal Interaction Restrictions

Classification Interacting Substance/Class Official Constraint
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Co-administration is formally prohibited. MAOIs prolong and intensify the anticholinergic and sedative effects of Adekin.
Use Restriction Elderly or Debilitated Patients Use is not recommended due to heightened susceptibility to adverse effects like dizziness and sedation.

Documented Pharmacodynamic Effects

Adekin may have additive central nervous system (CNS) depressant effects when combined with other substances that cause sedation.

  • CNS Depressants: This class includes alcohol, hypnotics, sedatives, tranquilizers, and antianxiety agents. The resulting effect is an increased risk of dizziness and drowsiness.
  • Serotonin-Enhancing Antidepressants: Adekin’s anti-serotonin activity may interfere with the therapeutic effects of these medicines, with regulatory reports noting a potential reversal of antidepressant efficacy.

Other Documented Interactions

There are no known interactions between Adekin and non-alcoholic food or drinks. However, the use of alcohol is included under the CNS depressant warning, contributing to additive depressant effects.

Mechanism of Action

Adekin functions as a first-in-class small-molecule inhibitor of the Adenosine Kinase (AK) enzyme. Its primary biological target is the AK active site, where it acts as a non-competitive inhibitor by binding to an allosteric pocket distinct from the adenosine substrate site. This interaction reduces the phosphorylation of endogenous adenosine to adenosine monophosphate (AMP) within the cytosol of cells, particularly within inflamed or ischemic tissues where extracellular adenosine concentrations are typically elevated. The intracellular consequence is a reduction in the metabolic clearance of adenosine. This reduced metabolism leads to an increase in the local steady-state concentration of extracellular adenosine. The system-level physiological consequence is the enhanced activation of surface adenosine receptors (A1, A2A, A2B, and A3) on local cell populations, including neurons and immune cells, thereby modulating overall inhibitory neuromodulation and local inflammatory cascades.

Dosage and Administration Information

Adekin is administered exclusively by the oral route, available as a 4 mg tablet and an oral solution (syrup) at a concentration of 2 mg per 5 mL. The usage pattern requires that the total daily amount be administered in divided doses, typically two or three times throughout the day. This schedule is used because the clinical effect of a single dose generally lasts for only four to six hours.

For adults, treatment is usually initiated at a dose of 4 mg three times a day. The dose is subsequently adjusted to achieve the desired response, with the typical daily range being 4 mg to 20 mg. The maximum daily intake in adults is set at 32 mg. The medicine may be taken with or without food, providing flexibility in scheduling the divided doses.

Usage instructions include specific maximum doses for pediatric groups. For children aged 7 to 14 years, the maximum daily intake is limited to 16 mg. For those aged 2 to 6 years, the maximum daily intake is 12 mg. When administering the liquid form, it must be accurately measured using an appropriate device. If a scheduled dose is missed, it is advised not to double the next dose; instead, the missed dose should be skipped and the normal dosing schedule resumed. Dosage must be individualized, and treatment should begin with the lowest effective dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Adekin


Evidence for Use in Allergic-Inflammatory Conditions

Research on Adekin has historically focused on its role in conditions characterized by inflammatory or irritative states, such as allergic rhinitis (hay fever) and urticaria (hives). Studies conducted over time have used various designs, including older, short-term Randomized Controlled Trials (RCTs) and different comparative research methods. These trials were used in research exploring how symptoms change over time by measuring outcomes linked to inflammatory or irritative states, such as measured changes in itching, sneezing, and swelling in both adults and pediatric patients.

Studies report how symptoms evolved in the observed populations, with findings describing patterns observed in the studies. Studies observed Adekin in research that measured outcomes related to physical discomfort. Research describes how symptoms were measured, but it is important to note the evidence quality varies across studies. Much of the foundational evidence comes from research that is several decades old. Due to this, comparative evidence is lacking between Adekin and newer, non-sedating H1-antihistamines. Long-term effects are not fully established when this medicine is used continuously for chronic conditions.


Evidence for Appetite Stimulation and Nutritional Support

Adekin was studied for its potential effects on outcomes related to systemic or functional imbalance, specifically poor appetite and difficulty gaining weight. Research has explored this use through Randomized Controlled Trials (RCTs), open-label studies, and systematic reviews. Studies monitored outcomes related to physiological strain or stress, primarily focusing on changes in body weight, BMI, and subjective reports of appetite using specialized scoring systems.

What is known about this area is that the findings were mixed and highly dependent on the study population and the underlying medical reason for the poor appetite. Evidence quality varies across studies, and there is a documented need for more high-quality, contemporary RCTs focused on young children. Data for certain groups remain insufficient, and research provides limited insight into the durability of weight gain or appetite support after the medicine is discontinued.


Evidence for Recurrent Neurovascular Discomfort

Adekin was evaluated in research exploring how symptoms change over time for conditions characterized by fluctuating or episodic manifestations, relevant to recurrent neurovascular discomfort. The evidence is primarily derived from settings with varying symptom burdens, including retrospective analyses, case series, and limited non-randomized studies.

The certainty remains low for this use. Evidence suggests patterns observed in the studies related to a reduction in episode frequency in a portion of the studied population; however, the evidence is limited due to the lack of high-quality, placebo-controlled RCTs. The majority of the studies are non-randomized, meaning research does not determine whether an individual will respond similarly, and this contributes to the finding that comparative evidence is lacking against established prophylactic treatments.

Key Studies & References

  1. Cyproheptadine - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (NIH)

Frequently Asked Questions (FAQ)

Common questions about Adekin (FAQ)

Q: Why do some people say Adekin makes them feel tired?

A: Regulatory documents classify drowsiness and somnolence (sleepiness) as common adverse reactions. These effects are typical for first-generation antihistamines. Official labeling indicates that these sedative effects are often transient and may lessen after the first few days of continuous administration.

Q: Can Adekin be taken with common over-the-counter pain relievers?

A: Official documents advise that Adekin may have additive central nervous system (CNS) depressant effects when combined with other substances that cause sedation, which includes hypnotics, sedatives, and tranquilizers. Reviewing official patient information regarding all concurrent medications is advised.

Q: Is it true that Adekin is not suitable for people with liver issues?

A: Adekin should be used with caution in individuals who have a history of hepatic, or liver, impairment. This caution relates to the drug's established safety profile in individuals with pre-existing conditions.

Q: What does the research say about the long-term use of Adekin?

A: Official reviews of the evidence note that long-term effects are not fully established when this medicine is used continuously for chronic conditions. Much of the foundational evidence for Adekin comes from older, short-term research, and comparative evidence against newer treatments is limited.

Q: Is Adekin commonly used in older adults?

A: Adekin is strictly contraindicated (prohibited) in debilitated geriatric patients. Use in other elderly patients requires caution. This caution is based on regulatory guidelines noting a heightened susceptibility to adverse effects, such as dizziness and sedation, in this population.

Q: Does Adekin cause weight gain or weight loss?

A: Official prescribing information lists increased appetite and associated weight gain as a documented adverse reaction of Adekin. This effect is specifically noted in the official adverse reactions information.

Q: Can Adekin be taken with food, or does it need to be on an empty stomach?

A: According to official usage instructions, the medicine may be taken with or without food. This allows for flexibility in the scheduling of the divided daily doses.

Q: Does Adekin interact with alcohol?

A: Official labeling includes alcohol under the central nervous system (CNS) depressant warning. Co-use with alcohol may contribute to additive CNS depressant effects, increasing the risk of symptoms like dizziness and drowsiness.

Q: Are there any known interactions between Adekin and common supplements like St. John's Wort?

A: Adekin’s action as a serotonin receptor antagonist means it may interfere with the therapeutic effects of serotonin-enhancing medicines, potentially reversing their efficacy. Discussing the use of herbal or common supplements with a healthcare provider is generally recommended.

Q: Is Adekin safe to use if I have kidney problems?

A: Regulatory information advises that Adekin should be used with caution in individuals who have a history of renal, or kidney, impairment. This is because the kidneys may be involved in the drug's clearance from the body.

Q: Is Adekin suitable for children?

A: Safety and effectiveness have been established for children 2 years of age and older. However, it is strictly contraindicated (prohibited) for use in neonates and premature infants.

Q: Are there specific food restrictions listed for Adekin?

A: Official regulatory information states there are no known interactions between Adekin and non-alcoholic food or drinks. This indicates there are no specific dietary restrictions required for the medicine itself.

Q: Can Adekin be taken while taking blood pressure medication?

A: Official labeling advises caution when Adekin is used in patients with pre-existing cardiovascular disease or hypertension (high blood pressure). The use of Adekin in combination with blood pressure medication requires evaluation by a healthcare provider.

Q: What happens if I forget a dose of Adekin?

A: Regulatory information advises against doubling the next scheduled dose if a dose is missed. Instead, the patient should skip the missed dose and resume the normal dosing schedule.

Q: What is the typical time frame for the initial evaluation of Adekin's effectiveness?

A: Regulatory documentation notes that the clinical effect of a single dose generally lasts for four to six hours, indicating the drug is rapidly active. The complete time frame for full therapeutic benefit in chronic use is not specifically defined in the provided regulatory texts.

Q: What happens when Adekin is stopped?

A: Research reports limited insight into the durability of effects (such as appetite support or weight gain) after the medicine is discontinued. Any changes to use of the medicine should be discussed with a healthcare provider.

Q: Is Adekin considered a high-risk medication?

A: Adekin is classified as a first-generation antihistamine with central nervous system effects. The official label outlines several absolute contraindications and a list of rare but clinically significant adverse reactions, which is typical for this class of medicine and defines its safety profile.

Q: What is the difference between Adekin and other similar treatments?

A: Adekin is classified as a sedating first-generation H1-antihistamine. It is distinct from newer compounds due to its unique dual mechanism: acting as both a potent H1-antagonist and an effective antagonist of serotonin receptors. This dual action allows for its established utility in specific conditions.

Q: Does Adekin have a warning about potential driving impairment?

A: Yes, regulatory documents contain a warning advising caution with activities requiring mental alertness and motor coordination, such as driving a car or operating machinery. This warning is due to the potential for diminished alertness, dizziness, and sedation.

Q: How quickly should someone expect Adekin to start working?

A: The clinical effect of a single dose generally lasts for four to six hours. This information indicates the drug is absorbed and begins to act shortly after administration.

Q: What is the general experience of people who have been on Adekin for a while?

A: Commonly documented adverse reactions are typically limited to drowsiness and somnolence, which are often transient. Other frequently documented effects include dizziness, dry mouth, nausea, and increased appetite with weight gain, as described in official regulatory documents.

Q: What are the most common reasons a doctor might tell someone they cannot use Adekin?

A: Regulatory guidelines strictly prohibit use in infants (newborn or premature), debilitated geriatric patients, and individuals with specific existing conditions such as narrow-angle glaucoma or certain gastrointestinal obstructions. These are the absolute contraindications.

Q: Why is Adekin recommended for this specific condition?

A: The medicine's utility is attributed to its dual action as a potent H1-antihistamine and an effective serotonin receptor antagonist. This mechanism allows it to modulate inflammatory responses and neurochemical pathways related to its established uses, such as appetite stimulation.

Q: Does Adekin require any special monitoring or testing while being used?

A: Official documents specify maximum doses for pediatric patients and advise caution in patients with hepatic or renal (liver or kidney) impairment. This often necessitates close monitoring of the patient's condition by a healthcare provider.

Q: How does Adekin compare to placebo in research studies?

A: Studies for its established uses, such as appetite stimulation and allergic-inflammatory states, have included Randomized Controlled Trials (RCTs). These trials often compare the drug's effects against a placebo (an inactive substance) to measure efficacy.

Q: Do studies suggest Adekin is more effective in certain age groups?

A: The maximum recommended daily dosage is strictly defined and differs between adult and various pediatric age groups. Research findings have been reported for both adult and pediatric populations.

Q: Can taking Adekin cause dry mouth or changes in taste?

A: Dry mouth is a commonly documented gastrointestinal adverse reaction. The official label does not specifically list changes in taste as a distinct adverse reaction.

Q: What should I do if I think Adekin isn't working for me?

A: If the medicine's effects are not as expected or if you have concerns about your treatment, the official recommendation is to seek guidance from the healthcare provider who prescribed the medication.

Q: Can Adekin make existing medical conditions worse?

A: Adekin is strictly contraindicated in patients with certain existing conditions, such as angle-closure glaucoma or specific gastrointestinal obstructions, as the use of the drug is associated with certain risks in individuals with these conditions.

Q: Why does the official document describe Adekin's purpose this way?

A: Official documents use specific regulatory terminology to define the drug's purpose and action. This language focuses on the clinical outcomes and the primary mechanism of action, such as its dual role as an H1-antihistamine and a serotonin receptor antagonist.

Q: Does Adekin cause dizziness?

A: Dizziness is one of the commonly documented adverse reactions associated with the medicine's effects on the central nervous system.

How should Adekin be stored and disposed of?

Adekin should be stored at room temperature, away from moisture and heat. It is critical to keep this, and all medications, out of the reach of children and pets. Always store the drug in its original, labeled container.

Disposal Guidelines

To dispose of unused or expired Adekin, the preferred method is to utilize a community drug take-back program. These programs ensure proper, safe, and environmentally sound disposal. You can check with local pharmacies or law enforcement for authorized collection sites or periodic take-back events.

If a take-back program is not readily available, most medicines can be safely disposed of in the household trash. This should be done by mixing the tablets or capsules with an undesirable substance, such as used coffee grounds or cat litter, without crushing the pills. This mixture should then be placed in a sealed bag or container to prevent leakage before being thrown into the trash. Be sure to scratch out all personal information on the prescription label before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adekin found in:

A-Z Index: